Biogen (NASDAQ:BIIB) reported Q1 2017 results before the market opened on April 25. The stock then trended up, despite revenue growth since Q1 2016 being anemic.
The main event of Q1 was the spin-off of the blood diseases division, Bioverativ (NASDAQ:BIVV). Two of Biogen's fasting growing therapies, Alprolix and Eloctate, went with Bioverativ, but showed about a month's worth of revenue for Biogen in the quarter. Together they generated about $74 million in sales for Biogen. We will learn how much they generated for Bioverativ when the company reports on May 4.
